Grady Health System
Atlanta, Georgia, 30303, United States
NCT Number: NCT06448429
This study aims to test the use of an adapted collaborative care model for improving the health outcomes of adults diagnosed with type 1 diabetes (T1D). The duration of the study is 18 months with 4 study survey points. Participants will fill out an online survey regarding their psychosocial health and chronic disease management behaviors once every six months over the 18 months, and individuals who are randomly assigned to the study intervention will also consult at least once with a behavioral health consultant during the first year (active intervention period).
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
Atlanta, Georgia, 30303, United States
Type 1 diabetes (T1D) is a lifelong condition that requires consistent monitoring and management, increasing people's risk for common mental disorders that worsen diabetes self-care. Both depression and diabetes can be managed with behavioral interventions, however, they are rarely provided alongside routine diabetes care for people with T1D. In this research study, the investigators aim to evaluate the implementation and effectiveness outcomes of a collaborative care model that uses a Behavioral Health Consultant (BHC) to support lifestyle management among adults with T1D receiving diabetes care at the Grady Diabetes Clinic.
A trained clinical research coordinator will screen interested patients seeking treatment at the Grady Diabetes Center and conduct outreach to individuals who have been identified as having T1D within the Grady Diabetes Center's patient population.
Participants in the intervention group will engage with a behavioral health consultant (BHC) not affiliated with Grady who will work with them to establish personalized health goals and identify ways to manage stress and promote healthy behaviors as means to support their mental and physical health and meet their set goals (i.e., behavioral activation). Each session will be conducted over the telephone or Zoom and last 30-60 minutes, with the number and frequency of meetings established through discussions between the patient and BHC (typically 2-3 sessions for one year). Checklist and summary case reporting templates will be used to track intervention fidelity. The BHC will also participate in ongoing Zoom calls with the multi-disciplinary T1D clinical team at the Grady Diabetes Center once a month to provide updates on patients' behavioral health plans. Transitioning patients from the active intervention will involve discussions with the care team to ensure continued patient support. In cases of active suicidal ideation, the study team will notify the patient's usual diabetes care provider and the individual will be referred to psychiatric services at Grady.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will have the usual diabetes care at the Grady Diabetes Clinic.
Other names: Standard of Care (SOC)
Collaborative care will include:
The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care.
Other names: Integrated Care Model
Time frame: Baseline and 12 months
The proportion of patients achieving improvements in PHQ-9 score [PHQ-9<10] or a ≥50% PHQ-9 score reduction.
Time frame: Baseline and 12 months
Improvement in HbA1c will be considered as HbA1c<7 or ≥0.5% HbA1c reduction
Time frame: Baseline and 12 months
Researchers will use the Generalized anxiety disorder (GAD)-7, a 7-item scale with reporting scores from 0 to 3 on all the questions. It investigates how often the patient has been bothered by seven different symptoms of anxiety during the last two weeks with response options such as: " not at all," " several days '," more than half the days," and " nearly daily " scored as 0, 1, 2, and 3, respectively. The GAD-7 is scored by adding the scores for all 7 items, giving a total score from 0 to 21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate, and severe anxiety, respectively. Further evaluation is recommended when the score is 10 or greater.
Time frame: Baseline and 12 months
Systolic and diastolic blood pressure (SBP and DBP) will be extracted from participants' medical records.
Time frame: Baseline and 12 months
LDL cholesterol data will be extracted from participants' medical records.
Emory University
Other
Evaluating the Integration of Mental Health Care Into the Treatment of Type 1 Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06334133
Autoimmune Diseases, Diabetes Mellitus
Scottsdale, Arizona, United States
View Trial DetailsNCT05937321
Autoimmune Diseases, Diabetes Mellitus
Salt Lake City, Utah, United States
View Trial DetailsNCT07160816
Autoimmune Diseases, Diabetes Mellitus
Pirna, LÄK Sachsen, Germany
View Trial DetailsNCT05180591
Autoimmune Diabetes, Autoimmune Diseases
Charlestown, Massachusetts, United States
View Trial Details